Skip to main content Accessibility help
×
Hostname: page-component-84b7d79bbc-x5cpj Total loading time: 0 Render date: 2024-07-28T09:23:28.887Z Has data issue: false hasContentIssue false

15 - Baclofen

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Lioresal, Kemstro, Gablofen

Generic?

• Yes

Class

• Muscle relaxant

Commonly Prescribed for

(FDA approved in bold)

Spasticity and pain related to disorders such as multiple sclerosis (MS) or spinal cord diseases

• Trigeminal neuralgia

• Alcohol withdrawal

• Gastroesophageal reflux disease (GERD)

• Gilles de la Tourette syndrome (GTS)

• Tardive dyskinesias

• Chorea in Huntington's disease

• Acquired peduncular nystagmus

How the Drug Works

• Baclofen is a GABAB agonist. Through mechanisms in addition to GABAB’s inhibitory effect, it depresses monosynaptic and polysynaptic reflex transmission at spinal level but not neuromuscular transmission. However, the exact mechanism of action is unknown. It also has CNS depressant properties

How Long Until It Works

• Pain: hours to weeks

If It Works

• Slowly titrate to most effective dose as tolerated. Many patients will need gradual titration to maintain response and limit sedation

If It Doesn't Work

• Make sure to increase to highest tolerated dose – as high as 200 mg/day. If ineffective, slowly taper and consider alternative treatments for pain. In general, baclofen is more effective for spasticity related to MS or spinal cord disease than for other causes of spasticity

Best Augmenting Combos for Partial Response or Treatment-Resistance

• For focal spasticity, i.e., post-stroke spasticity, botulinum toxin is often more effective and is better tolerated

• Use other centrally acting muscle relaxants with caution due to potential synergistic CNS depressant effect

• Baclofen is usually used in combination with neuroleptics for the treatment of tardive dyskinesias or chorea

• Trigeminal neuralgia often responds to AEDs. Pimozide is another option. For truly refractory patients, surgical interventions may be required

Tests

• None required

ADVERSE EFFECTS (AES)

How the Drug Causes AEs

• Most AEs are related to CNS depression

Notable AEs

• Drowsiness, dizziness, weakness, fatigue are most common. Nausea, constipation, hypotension, and confusion

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 54 - 57
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Baclofen
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.016
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Baclofen
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.016
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Baclofen
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.016
Available formats
×